
-
Aclaris Therapeutics Inc. NasdaqGS:ACRS Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. Its Contract Research segment provides laboratory services. The company also develops ATI-1777, a soft JAK 1/3 inhibitor in Phase 2b trial for the treatment of atopic dermatitis and other dermatologic conditions; Bosakitug (ATI-045), an anti-TSLP monoclonal antibody in Phase 2a trial to treat moderate to severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and moderate to severe chronic obstructive pulmonary disease; ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor in Phase 2a trial for the treatment for T cell-mediated autoimmune diseases; Zunsemetinib (ATI-450), a mitogen-activated protein kinase-activated protein kinase 2 inhibitor under Phase 1b/2 trials for the treatment of metastatic breast cancer and pancreatic ductal adenocarcinoma; and ATI-052, a humanized anti-TSLP and anti-IL4R bispecific antibody in preclinical stage to treat various atopic, immunologic, and respiratory diseases, as well as an ITK selective inhibitor candidate for the treatment of autoimmune diseases. Aclaris Therapeutics, Inc. was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
Location: 701 Lee Road, Wayne, PA, 19087, United States | Website: https://www.aclaristx.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
55.26M
Cash
105.3M
Avg Qtr Burn
-3.079M
Short % of Float
6.81%
Insider Ownership
2.66%
Institutional Own.
88.26%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Phase 2b Data readout | ||
ATI-1777 (JAK 1/3 inhibitor) Details Atopic dermatitis, Skin disease/disorder | Phase 2b Update | |
Bosakitug (ATI-045) Details Asthma, Chronic rhinosinusitis with nasal polyps Big Mover™ Suspected Mover™ Susp. Mover™ | Phase 2 Data readout | |
Phase 2a Data readout | ||
Zunsemetinib (ATI-450) (MK2 inhibitor) Details Psoriatic arthritis | Phase 2a Update | |
ATI-2138 (ITK/JAK3 inhibitor) Details Autoimmune disease, Ulcerative colitis | Phase 2a Initiation | |
ATI-052 Details no known indication | Phase 1 Initiation | |
ATI-2231 (MK2 inhibitor) Details Solid tumor/s, Cancer, Pancreatic cancer, Metastatic breast cancer | Phase 1a Update | |
Zunsemetinib (ATI-450) Details COVID-19 | Failed Discontinued | |
Zunsemetinib (ATI-450) (MK2 inhibitor) Details Hidradenitis suppurativa | Failed Discontinued | |
Zunsemetinib (ATI-450) Details Rheumatoid arthritis | Failed Discontinued |